FIN 403

Drug Profile

FIN 403

Alternative Names: FIN403

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Finch Therapeutics
  • Developer Finch Therapeutics Group
  • Class Bacteria; Probiotics
  • Mechanism of Action Gastrointestinal microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Clostridium-difficile-infections

Most Recent Events

  • 23 Oct 2017 Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
  • 10 Mar 2017 FIN 403 is available for licensing as of 23 Feb 2017.
  • 02 Mar 2017 Finch Therapeutics completes a clinical trial in Clostridium infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top